Compliance to medications is crucial to outcomes after percutaneous coronary intervention (PCI). We sought to review sex differences in the use of guideline directed medications at discharge and during 1-year follow up after PCI from the multicenter prospective GenesisCare Outcomes Registry (GCOR) dataset.
Introduction:
Compliance to medications is crucial to outcomes after percutaneous coronary intervention (PCI). We sought to review sex differences in the use of guideline directed medications at discharge and during 1-year follow up after PCI from the multicenter prospective GenesisCare Outcomes Registry (GCOR) dataset.
Methods: From the GCOR multicenter Australian dataset we assessed discharge medications and compliance to medications over 1-year follow up in men and women.
Results. Out of 10,959 patients including 2500 (22.8%) women and 8456 (77.2%) men, women received less ASA (96.8% vs. 97.8%, p < 0.01). Despite undergoing PCI more often for ACS, women were less likely to receive ticagrelor (16.7% vs. 20.3%) or prasugrel (3.4% vs. 7.2%), p < 0.01 for both. Women received statins less often (91.3% vs. 94.2%, p < 0.01) and showed a trend for less ACEI/ARB use (67.3% vs. 69.2%, p = 0.067) without differences in use of beta blockers (58.7% vs. 58.1%) at discharge. At 1-year women received lower rates of nearly all guideline directed medications than men (Table) . Introduction: Whether guideline directed medication use and adherence varies by insulin treated diabetes mellitus (ITDM) compared to non-ITDM in women and men has not been previously reported.
Methods: From the GenesisCare Outcomes Registry we assessed discharge medications and compliance to medications over 1-year follow up in men and women by ITDM or non-ITDM status.
Results. A total of 624 women and 2031 men with diabetes mellitus underwent PCI during the study period, with 99% follow-up at 1-year. Women with ITDM vs. non-ITDM received similar rates ASA, ticagrelor, statins and beta-blockers, higher rates of clopidogrel or prasugrel and lower rates of ACEI/ARB. Men with ITDM vs. non-ITDM received lower rates of ASA and statins, similar rates of P2Y 12 inhibitors and higher rates of ACEI/ARB. At 1-year ITDM men continued to receive lower rates of statins but received beta-blockers more often than non-ITDM counterparts. Although there were no differences in guideline directed medication use by ITDM status at 1-year in women, rates were lower than in men (Table) .
